National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC)

Note that you will be prompted to log in or register an account

Accession Number
HLB01421717a

Study Type
Epidemiology Study

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period
October 2006 - September 2016

NHLBI Division
DCVS

Dataset(s) Last Updated
January 3, 2018

Clinical Trial URLs
NCT01322165

Primary Publication URLs
PMC3190125

Consent

Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research Yes

Commercial Use Specimen Restrictions Yes

Non-Genetic Use Specimen Restrictions Based On Area Of Use Yes

Genetic Use Of Specimens Allowed? Yes

Genetic Use Area Of Research Restrictions Yes

Specific Consent Restrictions
Use of data and/or biospecimens is restricted to research involving heart and blood vessel diseases. Study participants were given the option to consent to commercial use of DNA biospecimens, as well as for the creation of cell lines.

Objectives

The overall objective of GenTAC was to establish a registry of patients with genetically induced thoracic aortic aneurysms and related cardiovascular conditions, and collect associated medical data, as well as blood and tissue samples and make them available to investigators to advance research in diagnosis and management of genetically induced thoracic aortic aneurysms.

Background

Thoracic aortic aneurysms (TAAs) predispose individuals to life threatening aortic complications, including aortic dissection and rupture. The treatment of complications arising from TAAs is complex, with high rates of morbidity, mortality, and surgical procedures. TAAs are associated with loss of vascular smooth muscle cells and degeneration of extracellular matrix in the aortic wall. This degeneration may be caused by hypertension and inflammation, particularly in elderly individuals. Genetic mutations are the main cause of TAAs in many young or middle-aged individuals. Genetic disorders, such as Marfan syndrome, Loeys-Dietz syndrome, and vascular Ehlers-Danlos syndrome, have a high risk for TAA, and up to 20% of individuals with TAAs or dissection have a family history of TAAs without being affected by a known syndrome or known genetic mutation. While diagnostic and treatment advances have dramatically improved care for patients with genetically induced TAAs, many questions remain about how best to identify and treat these disorders. Thus, GenTAC was developed as a longitudinal registry for patients affected by genetically induced thoracic aortic conditions in order to facilitate ongoing and future investigations to improve the diagnosis and clinical management of patients with genetically induced TAAs. Information gained from studying the genetically induced TAAs is expected to benefit the clinical management of non-genetic TAAs, as well.

Participants

Eligible participants must have one of the following conditions: Marfan syndrome; Turner syndrome; Ehlers-Danlos syndrome; Loeys-Dietz syndrome; Shprintzen-Goldberg syndrome; FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 genetic mutation; bicuspid aortic valve; Familial Thoracic Aortic Aneurysm and Dissections; other thoracic aortic aneurysms and dissections (not due to trauma) in patients 50 years of age or less; or other congenital heart disease. Over 3,500 participants were enrolled.

Design

GenTAC was a longitudinal observational cohort study of affected individuals with either known or suspected genetic mutation that predisposes them for thoracic aortic aneurysms and dissections (TAAD). There were no interventions planned, and all decisions regarding approaches to treatment were to be made by the patients and their care teams. Enrollment data were abstracted from medical records or obtained through patient interviews. The data collected include clinical evaluations (by several organ systems), historically diagnosed conditions and outcomes and drug treatment; patient reported quality of life, co-morbidities, family history, smoking, alcohol use, and pregnancy history; most recent imaging evaluations, genetic testing, blood chemistry, and surgical interventions. When blood could not be collected from participants, a saliva sample was obtained as a source of DNA. Excess aortic tissue was frozen from participants that underwent surgery. Follow-up data was collected at regular intervals for each participant enrolled, with the interval varying by the diagnosis. Follow-up data include outcomes, clinical and imaging evaluations and treatment and lifestyle changes since the enrollment visit. Images were read by the imaging core according to the study protocol. Diagnosis of each participant was confirmed by the phenotyping core.

Conclusions

GenTAC established a vast biospecimen inventory and clinical database from over 3500 participants that is available to researchers with the ultimate goal of advancing the diagnosis and management of genetically induced thoracic aortic aneurysms and other cardiovascular complications. Some of the publications resulting from analysis of the GenTAC data and biospecimens can be found at https://www.nhlbi.nih.gov/research/resources/gentac/research.

Publications

A list of GenTAC publications can be found on the GenTAC Alliance website.

Additional Details

Subjects:

Updated 28th October 2025.

 

Total Subjects

Missing

3

Multiple

49

Marfan syndrome

770

Turner syndrome

266

Ehlers-Danlos syndrome, vascular

126

Ehlers-Danlos syndrome, other

21

Loeys-Dietz syndrome

90

FBN1, TGFBR1 or TGFBR2 genetic mutation

38

Bicuspid aortic valve w/out family history

790

Bicuspid aortic valve w/ family history

17

Shprintzen-Goldberg syndrome

*S

Familial Thoracic Aortic Aneurysm and Dissection

343

Other aneurysms/dissections of the thoracic aorta not due to trauma (<40 years old)

524

Other congenital heart disease w/ family history

106

1st or 2nd degree family member of probrand already enrolled in GenTAC

27

BAV with coarctation

67

Total

3,241

*S:  Values have been suppressed due to small counts.

Age:

 

Total Subjects

Missing

1,059

Discrepant

5

<10

101

10-19

336

20-29

267

30-39

344

40-49

440

50-59

421

60-69

200

70-79

57

>=80

11

Total

3,241

Sex:

 

Total Subjects

Missing

958

Male

1,282

Female

1,001

Total

3,241

Race:

 

Total Subjects

Missing

994

Discrepant

16

White

2,000

Black/African American

75

Asian

78

American Indian/Alaska Native

*S

Native Hawaiian/Pacific Islander

27

Mixed

46

Total

3,241

*S:  Values have been suppressed due to small counts.

 

 

Total Subjects

Missing

1,065

Discrepant

5

No

2,029

Yes

142

Total

3,241

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3 of the BioLINCC handbook describes the components of the review process

Material Types:

Aorta Tissue, Plasma, Whole Blood (limited), Lymphocytes, EBV Cell Line, DNA, Buffy Coat, Saliva (limited), PMNC/RBC Pellet

General Freeze/Thaw Status:

Updated 28th October 2025.

 

The vast majority of materials have zero thaws, with the exception of EBV cells (approximately half of which have been thawed).

Visits (Vials):

 

Aorta Tissue

Plasma

Whole Blood

Lymphocytes

EBV Cell Line

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Unknown

0

0

0

0

0

0

0

0

0

0

Draw 1

73

8.38

1,820

3.25

4

2.38

1,822

1.02

1,695

4.99

Draw 2

55

8.44

99

3.16

1

0.50

90

1.07

74

4.96

Draw 3

2

2.50

7

3.39

0

0

7

1.29

5

5.00

 

 

DNA

Buffy Coat

Saliva

PMNC/RBC Pellet

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Subject Count

Average volume (or vials) per subject

Unknown

1

49.00

0

0

0

0

0

0

Draw 1

3,024

85.50

858

1.00

57

2.16

870

2.10

Draw 2

77

104.56

60

1.02

18

2.11

55

1.98

Draw 3

5

115.21

5

1.00

0

0

5

1.80

Visits (Subjects):

Updated 28th October 2025.

 

Aorta Tissue

Subject Count

Average number of vials per subject

Draw 1

73

8.38

Draw 2

55

8.44

Draw 3

2

2.50

 

 

Plasma

Subject Count

Average volume (mL) per subject

Draw 1

1,820

3.25

Draw 2

99

3.16

Draw 3

7

3.39

 

 

Whole Blood

Subject Count

Average volume (mL) per subject

Draw 1

4

2.38

Draw 2

1

0.50

 

 

DNA

Subject Count

Average mass (ug) per subject

Unknown

1

49.00

Draw 1

3,024

85.50

Draw 2

77

104.56

Draw 3

5

115.21

 

 

Lymphocytes

Subject Count

Average number of vials per subject

Draw 1

1,822

1.02

Draw 2

90

1.07

Draw 3

7

1.29

  

 

EBV Cell Line

Subject Count

Average number of vials per subject

Draw 1

1,695

4.99

Draw 2

74

4.96

Draw 3

5

5.00

 

 

Buffy Coat

Subject Count

Average number of vials per subject

Draw 1

858

1.00

Draw 2

60

1.02

Draw 3

5

1.00

 

 

Saliva

Subject Count

Average volume (mL) per subject

Draw 1

57

2.16

Draw 2

18

2.11

 

 

PMNC/RBC Pellet

Subject Count

Average number of vials per subject

Draw 1

870

2.10

Draw 2

55

1.98

Draw 3

5

1.80


 

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Specimens and Study Datasets

Materials Available

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.